Detalles de la búsqueda
1.
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies.
JTO Clin Res Rep
; 2(2): 100103, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589981
2.
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.
J Thorac Oncol
; 15(2): 248-257, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778797
3.
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
J Thorac Oncol
; 14(6): 1046-1060, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30771521
4.
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.
Oncotarget
; 9(70): 33258-33270, 2018 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30279957
5.
Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Clin Lung Cancer
; 19(4): 301-314, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29396237
6.
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
Nat Med
; 24(10): 1627, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30104769
7.
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.
Nat Med
; 24(7): 1047-1057, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29892061
8.
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Clin Cancer Res
; 12(12): 3661-97, 2006 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16778094
9.
Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma.
Laryngoscope
; 127(4): 842-848, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27440393
10.
Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Clin Cancer Res
; 11(16): 6065-74, 2005 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16115952
11.
Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Clin Cancer Res
; 11(11): 4151-9, 2005 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15930351
12.
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.
Expert Opin Biol Ther
; 16(12): 1479-1489, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27650132
13.
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Clin Cancer Res
; 10(2): 658-67, 2004 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14760089
14.
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clin Cancer Res
; 10(9): 2968-76, 2004 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15131032
15.
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
Clin Cancer Res
; 8(2): 314-46, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11839647
16.
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Cancer Chemother Pharmacol
; 54(4): 308-14, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15184994
17.
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
Head Neck
; 36(4): 474-80, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23780650
18.
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Head Neck
; 36(11): 1547-54, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24123531
19.
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
Clin Cancer Res
; 19(13): 3671-80, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23757357
20.
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Clin Cancer Res
; 17(7): 1815-27, 2011 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21350000